March 11th 2025
IQVIA released a report detailing pharmacists’ authority to administer vaccines in the US as well as adults’ overall vaccination rates by state.
February 26th 2025
Beyond the Spots: Management of Measles
April 3, 2025 | 1:00 PM ET
View More
Pneumococcal Disease Prevention for Older Adults and the Pharmacist’s Role in an Evolving Vaccine Landscape
1.0 Credit / Immunization, Infectious Diseases
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
The Role of the Pharmacist in Influenza Prevention for At-Risk Adults: Strategies to Enhance Immunization
1.5 Credits / Infectious Diseases
View More
The Essential Role of Pharmacists in Improving Influenza Vaccination Coverage: Strategies to Increase Vaccine ...
1.0 Credit / Immunization, Infectious Diseases
View More
The Role of Pharmacists in Pneumococcal Prevention: Strategies to Improve Vaccine Uptake
1.0 Credit / Immunization, Infectious Diseases, Pulmonology
View More
Insights in Influenza Immunization: The Long-Term Care Pharmacist’s Role in Improving Health Outcomes in At-Ri...
1.0 Credit / Immunization, Infectious Diseases
View More
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
Moderna’s mRNA RSV Vaccine Shows Positive Results in Phase 3 Trial
January 3rd 2024The vaccine, called mRNA-1345, demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least 2 signs or symptoms and 82.4% against the disease with at least 3 signs or symptoms.
Nirsevimab Demonstrates Lasting Efficacy in Infants Through First RSV Season
October 28th 2023The drug, marketed as Beyfortus, was approved by the FDA in July for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.